Clinical Implications of Radiologic Occult Metastatic Disease in PDAC

In a retrospective study involving 366 PDAC patients undergoing neoadjuvant chemotherapy (NAC), 15% developed radiologic occult metastatic disease (ROMD). Key findings include the identification of elevated CA19-9 levels, indeterminate liver lesions, and enlarged para-aortic lymph nodes as significant risk factors. These findings suggest the need for enhanced preoperative imaging protocols. Patients with ROMD had a median overall survival of 15 months from diagnosis, emphasizing the importance of early detection and tailored treatment plans to improve outcomes. Common NAC regimen was FOLFIRINOX. Addressing ROMD through early intervention and tailored management is essential for improving patient survival. For a detailed review, access the study here.